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healthy and patients’ blood. HA BOECs were transduced with a
lentiviral vector carrying the B domain deleted form of FVIII
under the Vascular Endothelial Cadherin promoter (LV-
VEC.hFVIII) and were characterized for endothelial phenotype
and for the number of integrated LV copies/cell (*3). We ob-
served that FVIII was expressed by 80% of LV-VEC.hFVIII
transduced cells and was efficiently secreted in the supernatant.
Ten million LV-VEC.hFVIII-BOECs were transplanted intra-
peritoneally in association with cytodex 3 microcarrier beads in
NOD/SCID gamma-null HA mice (NSG-HA) (n = 6). BOECs
survived and secreted FVIII at therapeutic levels (12%) up to 18
weeks and ameliorate the bleeding phenotype of HA mice. Fi-
nally, LV-transduced HA BOECs were transplanted into a pre-
vascularized subcutaneous, scalable medical device (Cell
Pouch), optimized for sustained secretion of therapeutic FVIII
in NSG-HA mice, showing BOEC engrafted and activity up to
16 weeks post-transplant. These results pave the way for future
human clinical testing in HA patients by transplantation of GMP
produced autologous gene corrected BOECs with no sign of
tumorigenicity within this device.
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Current haemophilia therapies require frequent protein infusions
yet are unable to address long-term complications due to prolonged
trough periods with suboptimal factor levels. To overcome these
drawbacks, alternative modalities such as gene and cell therapies are
being investigated. Spheres made with AfibromerTM biomaterials
shield engineered human cells from immune rejection while pre-
venting the fibrotic foreign body response around the spheres, en-
abling sustained, therapeutic factor levels. To evaluate whether
sustained delivery of blood clotting factors by implantation of
spheres containing engineered human cells producing hFVIII, hFIX
or hFVII is dose adjustable and durable, various sphere doses were
administered intraperitoneally (IP) to murine wild-type and knock-
out disease models. Factor production was evaluated via a combi-
nation ofplasma protein levels, factor activity and bleeding (activity)
assays. Administration to wild-type mice resulted in sustained
plasma levels of blood clotting factors. Studies of FVIII-producing
spheres in haemophilia A knockout-mice resulted in dose-dependent
levels of functional hFVIII in plasma, with a corresponding cor-
rection of bleeding time and blood loss in a tail bleeding model.
Taken together, these data demonstrate that administration of
spheres made with Afibromer biomaterials shielding engineered
human cells results in sustained factor production and efficacious
correction of the bleeding phenotype in murine preclinical models.
The sustained factor levels achieved after a single IP implantation
create a viable alternative to traditional factor infusion or investi-
gational gene therapies, with several important advantages. We aim
to pursue first clinical studies in Haemophilia A patients and to
develop Shielded Living TherapeuticsTM products for other chronic
bleeding disorders.
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Exosomes are extracellular vesicles (50 -150 nm of diameter)
considered key elements for the intercellular communication.
Although they are proposed to be ideal vehicles for the targeting
of novel therapies, very little is known about the selectiveness and
specificity of the transference processes involving exosomes re-
leased from different cells. PEGylated Hollow gold nanoparticles
(PEG-HGNs) are near-infrared (NIR) responsive nanoparticles
(NPs) which are able to generate localized heat by the use of NIR
light leading to cell death when applying optical hyperthermia. In
this study, we demonstrate the selectivity of in vitro exosomal
transfer between certain cell types and how this phenomenon can
be exploited to develop new specific vectors for advanced thera-
pies. Firstly, PEG-HGNs were successfully incorporated in the
exosome biogenesis pathway of placental stem cells (MSCs) and
they were released as PEG-HGNs-loaded exosomes (PEG-
HGNs_MSCs_EXOs). Exosomes were characterized by confocal
microscopy, western blot, nanosight, zeta potential and electronic
microscopy. Afterwards, time lapse microscopy and atomic
emission spectroscopy demonstrated the selective transfer of the
secreted exosomes only to the cell type of origin when studying
different cell types including cancer, metastatic, stem or immu-
nological cells. Finally, the preferential uptake to selectively in-
duce cell death by light-induced hyperthermia was demonstrated.
This work highlights the potential of exosomes as advanced
therapeutic vectors and provides a better understanding to design
selective therapies for different diseases.
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Our laboratory is interested in the use of lentiviral vectors
(LV) for in vivo gene delivery and explores various envelope
pseudotypes for this purpose. Syncytins are fusogenic glyco-
proteins produced from endogenous retroviral sequences inte-
grated in the genome of vertebrates 25–45 millions years ago.
Syncytins are involved in many biological processes involving
cell fusion. We report the possibility to pseudotype LV with
murine syncytins A or B (LV-SynA and LV-SynB) and dem-
onstrate that these particles are infectious in the presence of
Vectofusin-1, a transduction adjuvant peptide, achieving titers of
1.4 – 1.2 E + 07 IG/mL (n = 14). LV-SynA or LV-SynB enable
high levels of transduction of B cells in vitro as shown with
A20IIA murine B lymphoma cells and with murine spleen pri-
mary CD19+ B220+CD3-B cells (respectively 88 – 10% and
89 – 4% transgene positive cells). Both immature and mature
murine bone marrow B cell subsets are efficiently transduced.
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